Enzimologia Molecular e Alvos de Drogas

• Página inicial do diário
• Arquivo
Autores
• Diretrizes para Autores
• Enviar manuscrito
Em detalhe
• Objetivo e escopo
• Ética de publicação
• Processo de revisão por pares
• direito autoral
• Contate-nos

Abstrato

The Knockout Punch for HER2 Positive Breast Cancer: Addition of an ADAM10 Inhibitor to the Combination Therapy of Trastuzamab and Lapatinib

Marcia L. Moss

The most popular drugs for treating HER2 positive breast cancer are Trastuzumab or lapatinib. Clinical trials in recent years have begun where the two drugs are now being used in combination. Some of the trial results appear to be promising and the combination therapy could provide a new way in which to combat resistance to therapies and improve disease free survival compared to when either drug is used alone. This article describes the benefit of targeting HER2 positive breast cancer with multiple therapies and proposes a novel way in which to treat the disease; to add an ADAM10 inhibitor to the Trastuzumab and lapatinib combination.